GlobeNewsWire · IMRX · November 4, 2026

Immuneering to Highlight Atebimetinib's Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium

Get the app for more

Explore stock news, insights and company research.